Literature DB >> 14968324

[Onychomycosis].

D Reinel1.   

Abstract

Onychomycosis is an infection of the finger-and/or toenails by fungal microorganisms. If untreated, the process advances and destroys the nail plate. It may spread to involve the skin and does not heal spontaneously. There are different clinical presentations of onychomycosis which vary with the nature of the fungus and how it invades the nail unit. These different clinical forms require different therapeutic approaches. The successful treatment of onychomycosis requires special knowledge of the various clinical presentations, of the differential diagnosis and of recent advances in medical mycology. Therefore onychomycosis is best treated by dermatologists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968324     DOI: 10.1007/s00105-003-0680-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  24 in total

1.  Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview).

Authors:  M Zaug; M Bergstraesser
Journal:  Clin Exp Dermatol       Date:  1992-09       Impact factor: 3.470

2.  "Endonyx" onychomycosis: a new modality of nail invasion by dermatophytes.

Authors:  A Tosti; R Baran; B M Piraccini; P A Fanti
Journal:  Acta Derm Venereol       Date:  1999-01       Impact factor: 4.437

Review 3.  Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview.

Authors:  P D Doncker; A K Gupta; G Marynissen; P Stoffels; A Heremans
Journal:  J Am Acad Dermatol       Date:  1997-12       Impact factor: 11.527

4.  The spectrum of nail disease in patients with human immunodeficiency virus infection.

Authors:  C R Daniel; L A Norton; R K Scher
Journal:  J Am Acad Dermatol       Date:  1992-07       Impact factor: 11.527

5.  A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.

Authors:  R Baran; M Feuilhade; P Combernale; A Datry; S Goettmann; P Pietrini; C Viguie; G Badillet; C Larnier; J Czernielewski
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

Review 6.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

7.  [Limits of brief treatment of onychomycoses].

Authors:  C Seebacher
Journal:  Hautarzt       Date:  1998-09       Impact factor: 0.751

Review 8.  How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data.

Authors:  E Epstein
Journal:  Arch Dermatol       Date:  1998-12

9.  Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days.

Authors:  J Faergemann; H Zehender; L Millerioux
Journal:  Clin Exp Dermatol       Date:  1994-03       Impact factor: 3.470

10.  Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.

Authors:  R K Scher; D Breneman; P Rich; R C Savin; D S Feingold; N Konnikov; J L Shupack; S Pinnell; N Levine; N J Lowe; R Aly; R B Odom; D L Greer; M R Morman; A D Bucko; E H Tschen; B E Elewski; E B Smith
Journal:  J Am Acad Dermatol       Date:  1998-06       Impact factor: 11.527

View more
  1 in total

1.  [Fungal nail infections--an update: Part 1--Prevalence, epidemiology, predisposing conditions, and differential diagnosis].

Authors:  P Nenoff; G Ginter-Hanselmayer; H-J Tietz
Journal:  Hautarzt       Date:  2012-01       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.